Jazz Pharmaceuticals News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

21.11.24	Zymeworks To Receive Milestone Payment From Jazz In Relation To FDA Approval Of Ziihera (RTTNews)
21.11.24	Jazz Pharma Gains FDA Accelerated Approval For Ziihera To Treat HER2-positive Biliary Tract Cancer (RTTNews)
30.10.24	Biotech Stocks Facing FDA Decision In November 2024 (RTTNews)
15.10.24	Jazz Pharma Reports Positive Topline Data From Phase 3 IMforte Maintenance Study In ES-SCLC (RTTNews)
04.09.24	Jazz Pharmaceuticals Announces Pricing Of Private Offering Of Senior Notes (RTTNews)
03.09.24	Jazz Announces Private Offering Of $850 Mln Senior Notes (RTTNews)
25.08.24	Weekly Biotech Buzz: AADI Trims R&D Jobs, JNJ Loosens Purse Strings, FDA Snubs REGN's Myeloma Drug (RTTNews)
23.08.24	Jazz Pharma: Phase 3 Trial Of Epidiolex For Rare Epilepsies Fails To Meet Primary Endpoint (RTTNews)
20.06.24	Jazz Pharma Says Phase 2b Trial Of Suvecaltamide In Essential Tremor Fails To Meet Primary Endpoint (RTTNews)
01.06.24	Jazz Presents Overall Survival & Longer Data From Trial Of Zanidatamab In Biliary Tract Cancer (RTTNews)
21.02.24	Jazz Pharma Names Eli Lilly's Philip Johnson CFO, Effective March 1 (RTTNews)
07.02.24	Jazz Pharma In Deal To Buy Redx Pharma's KRAS Inhibitor Program; Redx Stock Up (RTTNews)
14.11.23	IP Group: Autifony Signs Up To $770 Mln Worth Global Licencing Deal With Jazz Pharma (RTTNews)
07.11.23	Jazz Pharma, MD Anderson Collaborate To Evaluate Zanidatamab In HER2-Expressing Cancers (RTTNews)
22.09.23	Jazz's Enrylaze Approved In EU For Acute Lymphoblastic Leukemia & Lymphoblastic Lymphoma Treatment (RTTNews)
12.09.23	Jazz Pharma Appoints Renee Gala As COO (RTTNews)
21.07.23	Jazz Pharma Gets Positive CHMP Opinion For JZP458 (RTTNews)
19.01.23	Jazz: Phase 2 Data Shows Zanidatamab's Potential As Foundational Treatment For HER2-positive MGEA (RTTNews)
03.01.23	Hikma Pharma Launches Authorized Generic Version Of Xyrem In U.S. (RTTNews)
21.12.22	Jazz Exercises Option To Continue Development, Commercialization Of Zymeworks Zanidatamab (RTTNews)
14.11.22	STAND UP TO CANCER LAUNCHES NEW RADIO PSA WITH JAZZ PHARMACEUTICALS TO ENCOURAGE LUNG CANCER SCREENING (PR Newswire)
19.10.22	Jazz Pharma To License Zymeworks' Zanidatamab For Total Potential Payments Of Up To $1.76 Bln (RTTNews)
19.10.22	Jazz Pharmaceuticals and Zymeworks Announce Exclusive License Agreement to Develop and Commercialize Zanidatamab, a HER2-Targeted Bispecific Antibody (PR Newswire)
28.06.22	Jazz : Phase 3 Trial Of Nabiximols Oromucosal Spray In MS Spasticity Fails To Meet Primary Goal (RTTNews)
09.05.22	Axsome Therapeutics Completes U.S. Acquisition of Sunosi® (solriamfetol) for Excessive Daytime Sleepiness Associated with Narcolepsy or Obstructive Sleep Apnea (PR Newswire)
10.01.22	Jazz Reaffirms FY21 Guidance; Aims $5 Bln Revenue In FY25 (RTTNews)
05.01.22	Jazz Pharma Publishes Full Data Set From Phase 3 Trial In Adults With Idiopathic Hypersomnia (RTTNews)
30.12.21	Jazz Pharma Enrolls First Patient In Phase 2 Trial Of JZP150 For Post-Traumatic Stress Disorder (RTTNews)
30.11.21	Jazz Pharma Announces Commercial Availability In Canada Of Zepzelca - Quick Facts (RTTNews)
31.08.21	Jazz Pharma Announces Health Canada Approval Of Sunosi - Quick Facts (RTTNews)
12.08.21	Jazz Pharmaceuticals Announces U.S. FDA Approval of Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution for Idiopathic Hypersomnia in Adults (PR Newswire)
12.08.21	Jazz Pharmaceuticals Announces U.S. FDA Approval of Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution for Idiopathic Hypersomnia in Adults (PR Newswire)
10.08.21	Stand Up To Cancer And Jazz Pharmaceuticals Collaborate To Fund Catalyst Research On Hard-To-Treat Cancers (PR Newswire)
10.08.21	GW Pharmaceuticals receives approval for EPIDYOLEX® (cannabidiol) from the MHRA for the treatment of seizures associated with tuberous sclerosis complex (PR Newswire)
10.08.21	GW Pharmaceuticals receives approval for EPIDYOLEX® (cannabidiol) from the MHRA for the treatment of seizures associated with tuberous sclerosis complex (PR Newswire)
03.08.21	Jazz Pharmaceuticals Announces Second Quarter 2021 Financial Results (PR Newswire)
03.08.21	Jazz Pharmaceuticals Announces Second Quarter 2021 Financial Results (PR Newswire)
27.07.21	Biotech Stocks Facing FDA Decision In August 2021 (RTTNews)
22.07.21	National Comprehensive Cancer Network® Adds Newly Approved Rylaze™ (asparaginase erwinia chrysanthemi (recombinant)-rywn) to Clinical Practice Guidelines in Oncology for Acute Lymphoblastic Leukemia (PR Newswire)
22.07.21	National Comprehensive Cancer Network® Adds Newly Approved Rylaze™ (asparaginase erwinia chrysanthemi (recombinant)-rywn) to Clinical Practice Guidelines in Oncology for Acute Lymphoblastic Leukemia (PR Newswire)
20.07.21	Jazz Pharmaceuticals to Report 2021 Second Quarter Financial Results on August 3, 2021 (PR Newswire)
20.07.21	Jazz Pharmaceuticals to Report 2021 Second Quarter Financial Results on August 3, 2021 (PR Newswire)
13.07.21	Jazz Pharmaceuticals Announces Rylaze™ (asparaginase erwinia chrysanthemi (recombinant)-rywn) Investor Webcast on July 20, 2021 (PR Newswire)
13.07.21	Jazz Pharmaceuticals Announces Rylaze™ (asparaginase erwinia chrysanthemi (recombinant)-rywn) Investor Webcast on July 20, 2021 (PR Newswire)
07.07.21	Santé Canada autorise Vyxeos®, la première avancée en chimiothérapie depuis plus de 40 ans chez les adultes atteints de leucémie myéloïde aiguë (LMA) (PR Newswire)
07.07.21	Canada Approves Jazz's Vyxeos To Treat High-risk Acute Myeloid Leukemia (RTTNews)
07.07.21	Health Canada Approves Vyxeos®, the First Chemotherapy Advance in over 40 years for Adults with High-risk Acute Myeloid Leukemia (AML) (PR Newswire)
07.07.21	Health Canada Approves Vyxeos®, the First Chemotherapy Advance in over 40 years for Adults with High-risk Acute Myeloid Leukemia (AML) (PR Newswire)
07.07.21	Horizons ETFs Rebalances Marijuana-Focused Index Etfs (PR Newswire)
07.07.21	Horizons ETFs Rebalances Marijuana-Focused Index Etfs (PR Newswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Part Grp Hldg	1’263.50	2.89 %	K V
Sonova Hldg	312.10	2.66 %	K V
Novartis	93.68	2.32 %	K V
Geberit	526.80	1.97 %	K V
Roche Hldg G	254.30	1.27 %	K V
Kuehne+Nagel Int	209.50	0.72 %	K V
UBS Group	28.30	0.57 %	K V
Givaudan	3’933.00	0.36 %	K V
Nestle	76.00	0.05 %	K V
Lonza Grp	521.40	-0.04 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu Jazz Pharmaceuticals PLC

Aktien Top/Flop

Meistgelesene Nachrichten